Introduction
Humans have recently undergone explosive growth [1] , leading to an excess of rare genetic variation across diverse global populations [2] with largely unknown impacts on human traits. Accurate characterization of these variants and their functional significance can reveal novel drivers of rare diseases [3] [4] [5] , modifiers of common disease risk [6, 7] , and potentially protective variants and therapeutic targets [8, 9] . Major efforts to identify impactful rare variants have focused on protein-coding regions of the genome due to the relative cost of exome sequencing compared to whole-genome sequencing and the ease of identifying impactful variants in protein-coding regions from primary sequence data alone ( table 1 ) . However, protein-coding variants comprise only a subset of potentially impactful variation in an individual's genome -to address this shortfall in genome interpretation, new approaches are needed that can identify impactful rare variation in the non-coding genome.
In this review, we summarize recent loss-of-function studies focused on coding variation -these studies have revealed both a gene's tolerance and intolerance for lossof-function mutations, thereby aiding in identifying the genetic basis of multiple Mendelian disorders and guid-
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ing our understanding of the challenge in identifying and interpreting impactful variants in the non-coding genome [3] [4] [5] . We then address efforts to characterize rare variation in the non-coding genome by focusing on existing knowledge and emerging experimental and computational technologies that serve as a transition point to whole-genome interpretation. We conclude by discussing how such improvements are deepening our understanding of the role of rare non-coding variation in disease risk and how a more complete assessment of rare variation in the context of an individual's genomic background will be fundamental to personalized genomics and precision health.
Loss-of-Function Variation in Human Populations
Recent gene sequencing efforts in large population cohorts have identified an abundance of rare variants. Nelson et al. [9] sequenced 202 genes in 14,002 individuals and found that more than 95% of the discovered variants had allele frequencies less than 0.5%. Similarly, Tennessen et al. [10] sequenced the exomes of 2,440 individuals and found that ∼ 96% of predicted functionally important variants are rare. With estimates of the de novo mutation rate between 1.1e-8 and 1.4e-8 and the current human population size of 7 billion people, it is possible to predict that every possible mutation is tested approximately 80 times a generation. Population-scale sequencing efforts such as the 1000 Genomes Project have shown that many protein-coding mutations, including nonsense, splice site-disrupting, or frameshift mutations, have a high probability of causing loss-of-function phenotypes [11] . Indeed, it was remarkable to find that there were often multiple protein-coding loss-of-function variants that would cause partial or full inactivation of their respective genes in every healthy individual sequenced.
Deciphering the prevalence of loss-of-function variants and their phenotypic consequences has required studies in well-phenotyped population cohorts with thousands to tens of thousands of individuals. In Finland, 83 loss-of-function variants enriched in Finnish individuals were identified through exome sequencing of 3,000 individuals and then tested for their association with 60 phenotypes in 36,262 Finns [12] . Five of these variants showed genome-wide significant associations, with the most notable being a splice variant in the LPA gene that conferred protection against cardiovascular disease. Two recent studies in Pakistani individuals have also highlighted tens of thousands of rare, protein-coding loss-offunction alleles. Narasimhan et al. [13] exome sequenced 3,222 individuals and found 16,708 loss-of-function variants, 847 of which were homozygous in 781 genes. On average, they observed 1.6 heterozygous recessive lethal loss-of-function variants per adult. Additionally, they identified 38 individuals who were homozygous for rare loss-of-function variants in known recessive Mendelian disease genes. However, they observed no relationship [15] . By amassing exomes from 60,706 individuals, the ExAC authors identify 3,230 genes that lack any known loss-offunction alleles -of note, 79% of these genes have no known disease phenotype. This list acts as a rich resource for identifying potential Mendelian disease genes when narrowing down possible targets for individuals with severe, hereditary rare diseases. Additionally, the presence of natural human knockouts provides a unique opportunity to understand the in vivo consequence of rare phenotypes, whether beneficial or detrimental, and further provides new opportunities to uncover potentially druggable genes that confer minimal individual risk.
However, a major concern with the detection of impactful loss-of-function mutations has been that such variants are enriched for false positives [16] . Dissecting loss-of-function variants from sequencing noise or from true mutations that have no functional consequence has involved defining strict thresholds for variant calling and leveraging high-quality gene annotations. Gene expression data from RNA sequencing can aid in identifying the subset of loss-of-function mutations that induce functional consequences through nonsense-mediated decay (NMD) of the mRNA transcript [11] . For such analyses, an excess of allele-specific expression for loss-of-function alleles compared to their respective normal allele can inform degradation of the transcript by NMD. Studies of loss-of-function variation that have incorporated transcriptome data have demonstrated increased NMD surveillance for rare loss-of-function alleles compared to both common variants and predicted deleterious nonsynonymous variants [17, 18] . Furthermore, when studied across tissues, patterns of NMD for loss-of-function variants have exhibited only modest tissue heterogeneity with the vast majority of sites showing consistent patterns across tissues [17, 19] . As will be further discussed for non-coding variants, these studies demonstrate how the application of both genome and transcriptome data provides increased utility to detect true loss-of-function alleles in personal genomes.
So far, the identification of loss-of-function variation has been largely restricted to protein-coding regions because exome sequencing is relatively cheap and annotating putative loss-of-function variants in protein-coding regions is relatively easy. These studies have guided our expectations of the frequency of loss-of-function alleles for particular genes and ongoing challenges with interpretation of their phenotypic consequences. To characterize the full scope of human loss-of-function variation will require interpreting the non-coding genome; such variants have similar impacts on gene expression and protein abundance as coding loss-of-function variants, but the identification of causal non-coding alleles from primary sequence data remains a major bottleneck.
Non-Coding Loss-of-Function Variation
Currently, most interpretable and actionable variants are discovered by sequencing efforts focused on the protein-coding regions of the genome -a small fraction comprising less than 2% of the entire genome. Rapid interpretation of protein-coding variants has had exceptional impact on identifying rare variants contributing to rare genetic diseases such as Miller syndrome [4] , Kabuki syndrome [3] , and Schinzel-Giedion syndrome [5] . Despite these successes, current clinical sequencing efforts only manage to identify a causal, pathogenic variant for about 25-50% of cases ( table 2 ), suggesting that non-coding loss-of-function variants may underlie the etiology of many rare diseases. This was well articulated in a genomescale study of a family of 4 that identified a candidate locus for Miller syndrome and highlighted that an 'unknown fraction of important phenotypes in humans are encoded by non-exonic variants identified only by means of whole-genome sequencing' [20] .
So what evidence do we have for rare, pathogenic noncoding alleles? There are various mechanisms by which non-coding variants can elicit loss-of-function phenotypes, either by altering chromatin organization or disrupting proximal and distal regulatory elements ( table 1 ). Previous reviews have described a handful of examples of large-effect non-coding alleles underlying Mendelian disorders including beta-thalassemia and polydactyly [21, 22] . A systematic analysis of disease variants curated within the Online Mendelian Inheritance in Man (OMIM) and ClinVar databases reported over 27,000 variants connected to Mendelian diseases [23] . While these variants are certain to be of varying quality [24] , the authors reported that 29% were either upstream or downstream of their target gene, highlighting the fact that a significant fraction of variation associated to Mendelian disease resides in the non-coding genome. Indeed, specific examples of non-coding variants associated to Mendelian disorders continue to appear in the literature. Van Schil et al. [25] identified 4 promoter mutations that alter gene expression of SAMD7 and may contribute to autosomal recessive retinitis pigmentosa. Nellist et al. [26] applied exome sequencing to mutationnegative individuals with tuberous sclerosis complex and identified compelling variants of unknown significance affecting promoter regions. Likewise, Lin et al. [27] applied exome sequencing to 3 mutation-negative familial adenomatous polyposis families to identify a promoter deletion in 1 family. These authors highlight that many unresolved cases might be caused by yet to be discovered pathogenic non-coding variants and argue for wider genetic screening of these regions. Furthermore, additional pathogenic promoter and enhancer variants have been identified for autosomal dominant disorders such as congenital hereditary endothelial dystrophy 1 and adultonset demyelinating leukodystrophy [28, 29] . To date, however, there are no variants in non-coding regions that have a practice guideline curated by the ClinVar database or by the ACMG.
While there are several well-studied examples of largeeffect non-coding variants involved in Mendelian disorders, large-effect non-coding variants could be the exception and not the rule. Whereas the genetic code provides an effective tool for identifying consequential coding variants, there is no analogous resource for non-coding variants -that is, identifying non-coding mutations with strong priors on molecular consequences remains a significant challenge. While non-coding variants in promoters (like the examples given above) are often identified by exome sequencing, there is no specific method for iden- tifying which of these mutations significantly impact expression from sequence data alone. Such problems are greatly exacerbated in more distal non-coding regions outside the core promoter where there is a generally weaker prior on variant function. Additionally, the functional significance of specific non-coding variants may only be exposed in specific cell-or tissue-types or under particular environmental conditions, making it exceedingly difficult to identify disease-causing non-coding variants from sequence data alone.
To identify functionally significant non-coding regions and characterize the distribution of their effect sizes, massively parallel reporter gene assays (MPRAs) have recently been used to simultaneously test the impact of thousands of mutations on gene expression. By applying MPRAs and focusing on 2 enhancer regions, Melnikov et al. [30] observed mostly subtle changes in enhancer activity with the most extreme effects being centered on transcription factor binding sites and inducing 2-to 4-fold expression changes. Similarly, Patwardhan et al. [31] focused on 3 enhancers and reported that most expression changes were subtle, with only 3% inducing a fold change greater than 2-fold. In contrast, by focusing on the rhodopsin promoter, Kwasnieski et al. [32] reported that over 86% of tested substitutions had significant effects on expression, some as great as 30-fold. These distinctions may reflect technological differences or differences in the distribution of effects for targeted regulatory elements. However, each assay highlighted a small fraction of mutations that could induce at least a 2-fold change in expression.
So how do these results translate to genome-wide analyses or to known human variants? So far these studies have not been performed genome wide and have focused only on a small portion of the non-coding genome. By specifically coupling human genetic variation data to MPRAs, Vockley et al. [33] were able to more systematically test the effects of both common and rare non-coding variants in a region associated to adiposity at birth. From 283 testable variants, they identified 36 variants that had significant effects on expression -of these, 4 common variants had a greater than 2-fold effect on gene expression [33] . Ignoring the fact that multiple alleles are coinherited, the consequence of an individual being homozygous for one of these variants would reduce their expression by half and may be functionally equivalent to carrying a single loss-of-function protein-coding allele. MPRAs demonstrate that such large-effect non-coding changes are indeed possible in every regulatory sequence surveyed.
Because multiple alleles can be co-inherited, it is likely that deciphering combinations of allelic effects will be increasingly important when interpreting loss-of-function mutations. It is widely accepted that the genomic context of any mutation is important for understanding both its penetrance and phenotypic expressivity. This was well shown by a recent study of predicted deleterious proteincoding alleles that demonstrated how genes can harbor compensatory mutations, negating their detrimental effects [34] . Likewise, deciphering the interactions between regulatory variants and protein-coding loss-of-function mutation is important for interpreting the impact of any loss-of-function mutation. Two recent studies of Mendelian disorders described compound heterozygosity of promoter and protein-coding loss-of-function mutations [35, 36] . In both diseases, affected individuals are haploinsufficient; they carry a protein-coding loss-of-function mutation on 1 allele coupled with a mutation that reduces expression on the other allele. Furthermore, genomewide analyses of deleterious alleles have shown that potentially harmful protein-coding alleles are more often lowly expressed and such patterns are likely driven by differences in purifying selection influenced by the level of expression [17, 37, 38] . These observations highlight how interpretation of protein-coding loss-of-function variants will require interpreting their genomic context with respect to both protein-coding and non-coding alleles. This is even more important when interpreting variation in the non-coding genome -both expression quantitative trait loci (eQTL) studies and MPRAs have demonstrated how frequently multiple regulatory alleles can influence the expression of their co-inherited gene. As any additional regulatory allele can nudge a gene outside its desired range of activity, interpretation of non-coding lossof-function variants will undoubtedly include subtle effects that need to be contextualized on the activity of all other regulatory alleles carried by an individual.
From Exome to Genome Interpretation
The catalogue of potentially functional regulatory variants has rapidly expanded in recent years. Due to falling sequencing costs, it has become increasingly common for large genomics projects to sequence entire genomes rather than exomes. The final phase of the 1000 Genomes Project saw the release of genome sequencing data for 2,504 individuals sampled from global populations [2] . At the same time, large-scale genome sequencing efforts have been underway in specific populations across the globe, for example: 1,070 Japanese individuals [39] ; 2,120 Sardinian individuals [40] ; 2,636 Icelandic individuals [41] ; and 3,621 British individuals [42] . All in all, almost 12,000 people have been sequenced as part of a large, published research project. In order to better understand the contribution of rare variants to human traits, even more ambitious sequencing efforts are currently underway. The Saudi Human Genome Project is planning to sequence 20,000 individuals, Genomics England has launched the 100,000 Genomes Project, and the United States has announced the Trans-Omics for Precision Medicine Initiative (TOPMed) and the One Million Genomes Project. Researchers in China are planning to sequence a million human genomes as part of the 3-Million Genome Project, and the Korean Genome Project has a roadmap to sequence 1,000,000 genomes by 2020 and increasingly larger numbers in the subsequent years. These large collections of whole genomes will enable researchers to better understand the allele frequency distribution of both protein-coding and non-coding alleles, the distribution of loss-of-function effects, and the role of rare and extremely rare variants in complex and Mendelian disease.
With so much sequencing underway, functional interpretation of novel variants is rapidly becoming the bottleneck in research. Computational methods for predicting the functional impact of variation can be broken up into two major classes. The first class of algorithms, such as SIFT [43] and PolyPhen-2 [44] , aimed at identifying the impact of mutations in protein-coding regions of the genome. These methods take advantage of gene models, the genetic code, and conservation identified by multiple species alignment to identify putative loss-of-function mutations that introduce premature stop codons (stop-gains), abrogate existing stop codons (stop-loss), alter splice donors/acceptors, or dramatically alter the biochemical properties of individual residues. These methods play critical roles in exome interpretation pipelines [45] [46] [47] , but are, of course, limited in their application to the noncoding genome. One complexity with variant interpretation in the non-coding genome is that there are various mechanisms by which non-coding variation can function -while many common regulatory elements act in cis [48] , trans and long-range interactions dramatically increase the number of potential regulatory variants for any given gene and these interactions can have a dramatic impact on disease risk [49] [50] [51] . Additionally, these regulatory effects can be specific to certain cell/tissue types, certain developmental stages, or environmental conditions [52] [53] [54] , making it difficult to predict phenotypic variation (e.g. gene expression) as a function of sequencelevel variation without additional data.
Despite these challenges, a significant amount of work has been done in order to develop methods that can more readily identify functional genetic variation, regardless of whether said variation is coding or non-coding. The first major research in this area focused on identifying functionally significant genomic regions using phylogenetics -that is, by comparing orthologous sequences across several species, methods such as PhyloP [55] , phastCons [56] , and GERP [57] can estimate the evolutionary constraint at individual base pairs. While such conservation metrics have been very successful at identifying regions of the genome under strong purifying selection (e.g. coding sequences), they fail to effectively identify functional regulatory variants that are generally under weaker purifying selection than coding variants [58] .
To overcome this limitation, newer methods have sought to integrate conservation data with other relevant genomic annotations that have been produced by largescale functional genomics projects like the Encyclopedia of DNA Elements (ENCODE) project [59] and the Roadmap Epigenomics project [60] . These 2 projects have produced genome-wide maps of transcription factor binding sites, chromatin accessibility, and various histone modifications across a wide range of human cell types. Together, these data can be used to demarcate regions of functional significance in the genome. The public release of these datasets has led to several novel computational methods that attempt to identify functionally significant variants. For example, the combined annotation-depletion dependent (CADD) software [61] and the genomewide annotation of variants (GWAVA) software [62] integrate a variety of functional data regarding chromatin state and accessibility, conservation, and transcription factor binding in order to build discriminative classifiers to identify functionally significant variants. Another method, fitCons [63] , estimates the extent of selective pressure on similarly annotated regions of the genome as a proxy for the functional relevance of variants in these regions. Eigen [57] uses an unsupervised method to calculate a functional score for both coding and non-coding variants based on relevant annotations in each region, based on the assumption that variants are either functional or non-functional. Finally, the gkm-SVM [64] algorithm can identify functional regulatory variants in specific cell types after being trained on appropriate regulatory sequences (e.g. open chromatin regions for the cell type of interest). It is important to note that many of these supervised learning programs (GWAVA, CADD, and gkm-SVM) rely on training data sets, which can be of varying quality and can limit technical performance in non-coding regions of the genome. Altogether, this rapidly expanding set of tools is enabling the functional interpretation of both rare and common non-coding variants. For convenience, we provide a table summarizing the reference datasets and tools we have discussed and how to access them ( table 3 ) .
Integrating Functional Genomics Data to Interpret Rare Alleles
Unfortunately, even with these new, integrative approaches it is still difficult to identify the regulatory impact of specific variants in the absence of additional functional data from carriers. In order to characterize variants that define the regulatory architecture of the human genome, there has been a significant push to identify eQTL in increasingly large and diverse cohorts, across different environmental contexts, and across human tissues [65] [66] [67] [68] [69] [70] . However, these studies have largely focused on the impact of common variants on gene expression due to statistical limitations in how eQTLs are conventionally identified.
While methods for identifying rare regulatory variants are still evolving, the typical approach is to identify individuals that have extreme gene expression phenotypesfor example, an individual might significantly over-or underexpress a gene or have a unique signature of allelespecific expression. Early studies of Europeans and other populations from the 1000 Genomes project found an excess of rare variants near genes with extreme expression phenotypes [37, 65] . Since the frequency of rare variants is increased in related individuals, analyses of rare expression phenotypes in families can be particularly effective at identifying the impact of rare regulatory variants. That being said, however, it can still be difficult to identify the causal variant if there is linkage between rare variants segregating in a family. A study of a large European family demonstrated that family members who shared extreme regulatory phenotypes were more likely to share rare variants near affected genes and that genes affected by rare variants were more likely to be essential or associated with disease [71] . Recently, methods based on the identification of expression outliers have emerged [72] and have been used to identify autism genes where rare variants are associated with extreme variability in gene expression [73] . Similar analyses have been used to reveal the impact of rare regulatory variants and rare copy number variants in schizophrenia [74] . Furthermore, novel rare variant burden tests have demonstrated the dramatic enrichment of rare variants in the promoters of genes with outlier gene expression [75] . By using these outlier methods to identify rare regulatory variants and the growing number of reference transcriptomes being made available, it is increasingly possible to identify rare non-coding variants that cause rare Mendelian diseases [76, 77] . Given the growing interest in using personal genomes and transcriptomes to diagnose rare disease, there is an increasing demand for methods that can more effectively identify rare regulatory variants. For example, current methods do not effectively integrate variability in total expression, allele-specific expression, or the effects of other common and regulatory alleles in order to identify rare regulatory variants. Additionally, improved efficiency of CRISPR/Cas9-mediated genome editing has made it increasingly feasible to validate putative rare regulatory variants [75] . While these experimental advances will surely drive the identification and validation of causal variants, increased data sharing amongst large genomics institutes through efforts like the Global Alliance for Genomics and Health (GA4GH) is expected to enable interpretation of rare variants on a global scale. For instance, the GA4GH Beacon project allows researchers anywhere to identify if a rare variant they are interested in has been previously observed. Similar technology for securely sharing clinical measurements, transcriptomes, and other functional genomics data will create an invaluable resource for researchers trying to characterize the function and pathogenicity of rare variants
Future Perspective
With the prospect of millions of genomes on the horizon, integration of rare, non-coding variants in the interpretation of personal genomes will require new paradigms in genomic analysis. Key to successful interpretation will be the development of in silico whole-genome interpretation approaches that leverage diverse and continually expanding genome and epigenome annotation data to propose candidate impactful alleles and their tissues, developmental stages, and environments of context. Integrating the impact of these alleles into personal genetic risk profiles will require multi-omics assays that can indicate if the non-coding allele significantly affects gene expression. Furthermore, revisiting family studies will improve our power to identify the distribution of large, segregating effects on gene expression and decipher their causal genetic architecture. These approaches will leverage expanding genome and cellular engineering techniques to measure effects in specific genome and cellular contexts. For instance, one can easily foresee leveraging the expanding epigenomics compendium to identify a potentially impactful non-coding variant, determining its context of activity, and then engineer cells from the same individual to measure genomic activity in relevant stages or environments.
Interpreting non-coding loss-of-function variants will require moving away from the narrow view of specific sites to considering the genomic context of multiple variants. An individual who is homozygous for a common variant that lowers expression may be more impacted by a rare variant that further reduces activity than an individual who naturally carries the higher expressing alleles. Understanding these epistatic effects will require understanding the thresholds at which gene expression transitions outside of the normal range of activity. Furthermore, it will require moving away from single genes to gene networks and pathways in order to identify how various genes can compensate each other or cumulatively add to an individual's risk of disease. The study of noncoding variants will transition the study of single variants to systems of variants and genes undoubtedly providing higher resolution and understanding of the impact of our genome on our health.
